卵巢癌腹腔积液中ERCC1表达与铂剂相关性研究

孔雁1，张宁1，贾琳2，左静1，张敏3，刘亮1，刘荣风1，姜达1

(1.河北医科大学第四医院,河北 石家庄 050000;2.河北省保定市第三医院,河北 保定 071000;3.河北省邢台市人民医院,河北 邢台 054000)

摘要：目的探讨卵巢癌恶性腹腔积液中ERCC1表达水平与铂类药物化疗疗效及预后关系。方法存在恶性腹腔积液的晚期卵巢癌患者腹水标本65例，采用流式细胞术检测腹水肿瘤细胞ERCC1蛋白表达水平。Kaplan Meier生存曲线分析比较不同ERCC1表达水平患者的中位生存期和无病进展时间。结果ERCC1的阳性率为38.5%。ERCC1低表达者含铂方案化疗效果优于高表达者,但两者间的差异无统计学意义(P>0.05);ERCC1低表达的患者总生存期(overall survival，OS)明显长于高表达者(P=0.03)。结论腹腔积液中肿瘤细胞ERCC1表达与卵巢癌预后具有相关性，与铂剂化疗疗效的关系尚待进一步明确。

关键词：ERCC1；卵巢癌；腹腔积液；铂剂

中图分类号：R 737.31

DOI：10.3969/j.issn.1673-1492.2015.03.016

作者简介：单喜花(1968-),女，河北南皮人，主治医师，主要研究方向：宫颈病变；不孕不育。

作者简介：郑建兴(1976-)，男，河北唐山人，主治医师，主要研究方向：肝胆胰脾疾病的诊治。

Studies on Correlation between ERCC1 Expression and Platinum in Ovarian Carcinoma Ascites

KONG Yan1,ZHANG Ning1,JIA Lin2,et al

(1.The Fourth Hospital of Hebei Medical University,Shijiazhuang 050000,Hebei China;

2.The Third Hospital of Baoding,Baoding 071000,Hebei China)

Abstract:ObjectiveTo investigate the expression of excision repair cross complementation group 1(ERCC1)in ovarian carcinoma ascites and explore the correlation of ERCC1 expression with therapeutic effect of cisplatin and survival time.MethodsAscites were collected from 65 patients from March 2012 to March 2014 at the Fourth Hospital of Hebei Medical University,while the expression of ERCC1 protein was studied by immunocytochemistry staining,and Kaplan Meier survival curve analysis was used to compare median overall survival time and median progression free survival time among the patients of with different expression of ERCC1.ResultsThe positive rates of ERCC1 expression in ovarian Carcinoma samples were 38.5%,while the therapeutic effect of cisplatin in patient with ERCC1 low expression was obviously better than that with ERCC1 high expression(P>0.05).The median overall survival time and progression free survival time of patients with ERCC1 low expression were obviously longer than that with high expression(P=0.03).ConclusionsThe ERCC1 expression in ascites could correlate with prognosis in ovarian carcinoma.

Key words:ERCC1；ovarian carcinoma;ascites;cisplatin

卵巢癌是女性常见恶性肿瘤，治疗以含铂方案化疗为主，根据对铂类的敏感程度，分为铂剂敏感及铂剂耐药两大类型，对铂类药物原发及继发耐药是导致化疗失败、病情进展的主要原因。然而，目前缺乏铂剂疗效预测因子，在治疗初期无法判断患者对铂剂的敏感程度，故化疗方案的选择有一定盲目性。已有研究表明，卵巢癌组织中DNA修复基因核苷酸切除修复交叉互补基因1(excision repaircross complementation group 1,ERCC1)不仅是生存预后指标，也可能预测含铂化疗方案的疗效。我们……